Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients w...

Full description

Bibliographic Details
Main Authors:	Yan Gao, Yuan Li, Chunyu Zhang, Jinsong Han, Huamao Liang, Kun Zhang, Hongyan Guo
Format:	Article
Language:	English
Published:	BMC 2019-09-01
Series:	Journal of Ovarian Research
Subjects:	Advanced ovarian epithelial Cancer Neoadjuvant chemotherapy Primary Debulking surgery Chemoresistance Prognosis
Online Access:	http://link.springer.com/article/10.1186/s13048-019-0562-9

Similar Items

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
by: Xingyu Liu, et al.
Published: (2023-06-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
by: Shi‐Ping Yang, et al.
Published: (2022-07-01)

Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
by: Lu Qin, et al.
Published: (2018-06-01)

Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer
by: LIU Chuanzhong, et al.
Published: (2018-10-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
by: Mengdi Fu, et al.
Published: (2022-01-01)

Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study
by: Guangming Cao, et al.
Published: (2023-03-01)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
by: Mengmeng Lyu, et al.
Published: (2022-09-01)

Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India
by: Debabrata Barmon, et al.
Published: (2023-10-01)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
by: Yuan Li, et al.
Published: (2023-02-01)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
by: Yong Jae Lee, et al.
Published: (2022-07-01)

The role of minimally invasive surgery in epithelial ovarian cancer treatment: a narrative review
by: Matteo Generali, et al.
Published: (2023-06-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
by: Cheng Li, et al.
Published: (2024-05-01)

Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer
by: Kazuki Takasaki, et al.
Published: (2024-08-01)

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond
by: Frank G. Lawton, et al.
Published: (2022-03-01)

Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
by: Sue Cheeseman, et al.
Published: (2023-01-01)

Prognostic Role of CRS in High Grade Serous Ovarian Tumour Patients Receiving Neoadjuvant Chemotherapy in a Tertiary Care Hospital of Central India
by: Manal Ashraf Ali, et al.
Published: (2022-05-01)

Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy
by: Ponganun Tuntinarawat, et al.
Published: (2024-04-01)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
by: Mackenzie Cummings, et al.
Published: (2022-04-01)

Optimal debulking surgery in ovarian cancer patients: MRI may predict the necessity of rectosigmoid resection
by: Xiaofang Zhao, et al.
Published: (2024-06-01)

Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
by: Merlo Sebastjan, et al.
Published: (2021-08-01)

Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (≥70 y): Does the Age Matter?
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?
by: Okan Aytekin, et al.
Published: (2024-07-01)

Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
by: Emre Günakan, et al.
Published: (2020-01-01)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
by: Huan Wang, et al.
Published: (2022-06-01)

Current Status and Controversies in Neoadjuvant Chemotherapy for Advanced Stage Ovarian Cancer: A Review
by: Jiaxi Li, et al.
Published: (2023-11-01)

Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram
by: Wei-feng Liang, et al.
Published: (2020-10-01)

The dual edges of neoadjuvant chemotherapy in advanced epithelial ovarian cancer: Therapeutic potential and clinical dilemmas
by: Li Jia, et al.
Published: (2024-12-01)

Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery
by: Yue-min Hou, et al.
Published: (2022-05-01)

The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study
by: Dairui Dai, et al.
Published: (2022-02-01)

Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer
by: Li-yuan Feng, et al.
Published: (2020-03-01)

Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay
by: Julia Heikkinen, et al.
Published: (2024-09-01)

Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer
by: Yue Jia, et al.
Published: (2024-02-01)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
by: Hyunji Lim, et al.
Published: (2022-06-01)

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
by: Renata A. Tassi, et al.
Published: (2017-05-01)